

1 Active site conformational fluctuations promote the enzymatic activity
2 of NDM-1

3
4 Hongmin Zhang^{a#}, Guixing Ma^a, Yifan Zhu^a, Lingxiao Zeng^b, Ashfaq Ahmad^a, Changzhi Wang^a,
5 Bo Pang^b, Huiyan Fang^c, Liqing Zhao^c, Quan Hao^{b#}

6
7 ^aDepartment of Biology, Guangdong Provincial Key Laboratory of Cell Microenvironment and
8 Disease Research, Shenzhen Key Laboratory of Cell Microenvironment and SUSTech-HKU
9 joint laboratories for matrix biology and diseases, Southern University of Science and
10 Technology, Shenzhen 518055, China

11 ^bSchool of Biomedical Sciences, The University of Hong Kong, Hong Kong SAR, China

12 ^cCollege of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen,
13 Guangdong 518060, China

14 Running title : *Conformational fluctuation promotes enzymatic turnover*

15
16 #Correspondence should be addressed to Prof. Hongmin Zhang (email: zhanghm@sustc.edu.cn
17 [or hongmin_zhang@foxmail.com](mailto:hongmin_zhang@foxmail.com)) or Prof. Quan Hao (email: qhao@hku.hk)

18
19 Keywords: microbial antibiotics resistance, metallo-beta-lactamase, NDM-1, conformational
20 change, structure-based drug design

22 **Abstract**

23 Beta-lactam antibiotics are the mainstay for the treatment of bacterial infections. However,
24 elevated resistance to these antibiotics mediated by metallo- β -lactamases (MBL) has become
25 a global concern. New Delhi metallo- β -lactamase-1 (NDM-1), a newly added member of the
26 MBL family that can hydrolyze almost all β -lactam antibiotics, has rapidly spread all over the
27 world and posed serious clinical threats. Broad-spectrum and mechanism-based inhibitors
28 against all MBLs are highly desired, but the differential mechanisms of MBLs towards
29 different antibiotics pose a great challenge. To facilitate the design of mechanism-based
30 inhibitors, we investigated the active-site conformational changes of NDM-1 through the
31 determination of a series of 15 high-resolution crystal structures in native form and in
32 complex with products, biochemical and biophysical studies, site-directed mutagenesis and
33 molecular dynamics computation. The structural studies reveal the consistency of the active
34 site conformations in NDM-1/products complexes and the fluctuation in native NDM-1
35 structures. The enzymatic measurements indicate a correlation between enzymatic activity
36 and the active site fluctuation with more fluctuation favoring higher activity. This correlation
37 is further validated by structural and enzymatic studies of the Q123G mutant. Our
38 combinational studies suggest that active site conformational fluctuation promotes the
39 enzymatic activity of NDM-1, which may guide further mechanism studies and inhibitor
40 design.

41

42 **Introduction**

43 Beta-lactam antibiotics, including penicillins, cephalosporins and carbapenems,
44 constitute more than half of the antibiotics prescribed in clinical settings(1). However, the
45 efficiency of these antibiotics is being continuously challenged by the emergence of resistant
46 pathogenic bacteria, among which resistance to carbapenems is of extreme concern for that
47 carbapenems are considered as the last resort for multidrug resistant infections. Beta-
48 lactamases, which inactivate β -lactam antibiotics through hydrolyzing the β -lactam bonds(2),
49 play a major role in antibiotic resistance(3, 4). Based on sequence similarity, β -lactamases
50 can be divided into four classes (A, B, C and D)(5). Enzymes in classes A, C and D are
51 serine- β -lactamases which harbor a serine residue at the active site to facilitate catalysis. And
52 members of class B are metallo- β -lactamases (MBLs) that retain one or two zinc ions at the
53 active site to facilitate β -lactam cleavage. MBLs are broad-spectrum β -lactamases, active
54 against almost all β -lactams including carbapenems and even the clinically used inhibitors of
55 serine- β -lactamases(6). Furthermore, most of the circulating MBLs are encoded in a
56 transferable plasmid which may be rapidly disseminated in different strains and even
57 different species of bacteria through horizontal gene transfer(7). For example, New Delhi
58 metallo- β -lactamase-1 (NDM-1) is a newly added member of the MBL B1 subclass and since
59 its first identification in 2009(8), NDM-1 positive bacteria have been identified in all
60 continents except Antarctica(9).

61 NDM-1 shows broad activity at all β -lactam antibiotics except monobactams(8). Because
62 of its rapid dissemination not only in clinical settings but also in community environments(10,
63 11), NDM-1 positive bacteria have posed a serious threat to our health care system. Since it
64 identification in 2009, much effort has been put on the biochemical characterization(12-15),
65 structural and mechanical studies(16-30), and inhibitor screening(31-35). It is highly
66 desirable to find some potent specific inhibitors for NDM-1 or even broad-spectrum

67 inhibitors for all MBLs. However, because of the structural diversity of MBL active sites, the
68 continuous evolving of these enzymes and the fact that very few residues are tightly
69 constrained by function, the design of broad-spectrum MBL inhibitors is very challenging(6).
70 Therefore, the design of MBL inhibitors may be best achieved by mimicking the focused
71 nature of interactions observed in both substrate recognition and the catalytic mechanism(6)
72 as in the case of serine β -lactamases. Unfortunately, the catalytic mechanism of NDM-1 is
73 subtle and some detailed roles of active site residues are still under debate, such as substrate
74 coordination(23, 26, 36), the individual roles of the two zinc ions, the identity and source of
75 hydroxide for nucleophilic attack(16, 23, 26, 27), the protonation of β -lactam nitrogen after
76 C-N bond cleavage(16, 23, 26) and the source of the next hydroxide for enzymatic
77 turnover(23, 26) etc. Recent spectroscopic and structural investigations made significant
78 progresses in the mechanism study of MBLs, but did not get to a consistent conclusion on the
79 hydrolysis of carbapenems by NDM-1(29, 37), suggesting further study for the sake of
80 mechanism-based broad-spectrum inhibitor design.

81 In this work, we investigated the conformational changes of the active site through the
82 combination of crystallography, site-directed mutagenesis, enzymatic measurements and in
83 silico simulation. Our results indicate a dynamic active site and its conformational fluctuation
84 promotes the enzymatic activity of NDM-1, which may guide future inhibitor design.

85

86 **Results**

87 **NDM-1 in complex with hydrolyzed antibiotics**

88 In our previous study(16), we solved the first NDM-1 structure in complex with a
89 hydrolyzed ampicillin and noticed that the distance between the two zinc ions at the active
90 site was 4.6 Å, which was much longer than those of other MBLs. We proposed that this
91 longer distance might correlate to the relatively lower enzymatic activity of NDM-1

92 compared to other B1 MBLs(16). And hence the longer distance might be an intrinsic
93 property of NDM-1 in the product binding state. However, there is also a possibility of being
94 a crystallographic artifact. To clarify if this longer distance is an intrinsic product binding
95 property or crystallographic artifact, we determined a series of NDM-1/Amp structures at
96 different crystallization conditions. As showed in Table 1, we re-crystallized NDM-1 in
97 complex with ampicillin at the same condition as our previously reported one and got the
98 highest resolution NDM-1/product structures up to now (1.00 Å). While the improvement of
99 resolution revealed more accurate details, we noticed that the new structures were almost
100 identical to that of previously solved one at the active site (Figure 1A). We further compared
101 the structures determined from crystals in different conditions, such as different pHs and
102 different precipitants. As shown by the first four structures in Table 1, although they were
103 crystallized in different pHs and even in high salt, the structures are almost identical and can
104 be superimposed with rmsd values ranging from 0.1 to 0.26 Å for all visible C α atoms
105 (Figure S1A for overall structure superposition). And besides overall structures, the active
106 site confirmations of these structures are also very consistent with that of previously solved
107 one with the Zn1-Zn2 distances ranging from 4.57 to 4.61 Å in 8 NDM-1 molecules, the
108 distances of Zn1-OH and OH-Zn2 averaged at 2.00 ± 0.05 Å and 3.01 ± 0.04 Å (Figure 1B),
109 respectively.

110 After our first report of NDM-1/Amp structure, several structures of NDM-1 in complex
111 with other hydrolyzed antibiotics were also reported as listed in Table 1. For these structures
112 of NDM-1 in complex with methicillin (4EY2)(22), oxacillin (4EYB)(22), benzylpenicillin
113 (4EYF)(22), cephalexin (4RL2)(27) and ampicillin (4H0D)(23), 4HL2(23) and 4RAW), the
114 overall structures are very similar with rmsd values ranging from 0.10 to 0.36 Å for all the
115 superimposed C α atoms (Figure S1B). And for the active sites of these structures, Zn1-Zn2
116 distances were ranging from 4.48 to 4.63 Å (average value of 4.56 ± 0.05) while the distances

117 of Zn1-OH and OH-Zn2 were $1.98 \pm 0.07 \text{ \AA}$ and $2.96 \pm 0.10 \text{ \AA}$ (Figure S2A), respectively. The
118 active site conformations observed in these structures are almost identical to those
119 determined in our studies.

120 However, for structures of NDM-1 in complex with hydrolyzed meropenem (4EYL(22),
121 5N0H and 4RBS), the Zn1-Zn2 distances were a little bit shorter (ranging from 3.83 to 4.05
122 \AA with an average $3.96 \pm 0.09 \text{ \AA}$). Inspection of these structures revealed that the hydrolyzed
123 meropenem did not bind the active site like other hydrolyzed antibiotics (Figure S2A) with
124 either the newly generated carboxylate group intercalating between the two zinc ions (4EYL
125 and 5N0H) or the side ring carboxylate group not coordinated to Zn2 (4EYL and 4RBS)
126 (Figure S2B). The intercalated conformation might be a rare binding state during product
127 release, which was also suggested from the QM/MM calculation(38) as a rare inhibition state.

128 The structure of NDM-1 in complex with a reaction intermediate of cefuroxime (4RL0(27))
129 showed shorter Zn1-Zn2 distances (3.81/3.83 \AA for two monomers) and OH-Zn2 distances
130 (2.16/2.17 \AA for two monomers). Active site inspection revealed that the newly generated
131 carboxylate group did not coordinate to Zn1 as other products did. The shorter distance
132 observed in this structure might be attributed to the reaction intermediate which needs further
133 investigation.

134 Overall, in all NDM-1 structures with the hydrolyzed antibiotics coordinated to the active
135 site in a product binding state, the Zn1-Zn2, Zn1-OH and OH-Zn2 distances are very
136 consistent to be 4.6, 2.0 and 3.0 \AA , respectively. This conformation should be an intrinsic
137 NDM-1/product binding state and not a crystallographic artifact.

138 **NDM-1 in native form**

139 Since the identification of NDM-1 in 2009, many structures of NDM-1 in native form and
140 in complex with antibiotics have been solved. Some of the reported structures showed no
141 metal, mono metal(19) or not properly coordinated residue-metal interactions at the active

142 site(39). A Zn-Cd substituted NDM-1(20) (PDB 3ZR9) was obtained at pH7.5 with the Zn-
143 Cd distance of 3.64 Å. While another structure(18) (PDB 3SPU) obtained at pH8.5 reported
144 5 molecules in the asymmetric unit and the Zn1-Zn2 distances ranging from 3.56 to 3.97 Å. It
145 was then proposed that the Zn1-Zn2 distance was affected by different pHs(23). To reveal a
146 clear and more accurate active site of native NDM-1 and what kind of factors can affect the
147 active site conformation, we determined a series of native NDM-1 structures in different
148 conditions including crystal packing, buffer components and pH variations.

149 *Effect of crystal packing*

150 In our search for native NDM-1 crystallization conditions, two crystal forms were
151 obtained with form 1 retaining one molecule in the asymmetric unit and diffracted up to 0.95
152 Å resolution while form 2 harboring two molecules and diffracted between 1.05 and 1.55 Å
153 depending on the crystallization precipitants (Table 2). For crystals of form 2, although they
154 were obtained in different pHs and different buffer components (HEPES pH7.0 and pH7.5,
155 imidazole pH7.5 and Tris pH8.0), the active site conformations are strikingly identical
156 (Figure 2A and Figure S3) with the Zn1-Zn2, Zn1-OH and OH-Zn2 distances of 3.39 to 3.43
157 Å, 1.93 to 2.11 Å and 1.95 to 2.13 Å, respectively (Table 2). The Zn1-Zn2 distance is also
158 consistent with the one measured by extended X-ray absorption fine structure study (3.38Å)
159 (21). However, when we compare the structures of NDM-1 in forms 1 and 2 obtained in the
160 same buffer and pH (imidazole pH7.5, PDB 5ZGZ and 5ZH1), we noticed that the Zn1-Zn2
161 distance in form1 is 3.62 Å while in form 2 it is 3.41/3.42 Å. The only difference between
162 these two crystals is crystal packing so that the Zn1-Zn2 distance is clearly affected by crystal
163 packing.

164 *Effect of buffer components*

165 Next, we compared the structures of form1 obtained at pH7.5 but prepared with different
166 buffer components (imidazole, Bis-Tris and succinate). Despite of being crystallized at the

167 same pH, these structures showed different Zn1-Zn2 distances of 3.62 Å in imidazole,
168 3.59/3.53 Å in succinate and 3.49 Å in Bis-tris (Table 2), respectively. Although the
169 differences are subtle, they can be repetitively observed, indicating that different buffer
170 components do affect the active site conformations.

171 *Effect of different pHs*

172 And then, we examined the pH effect on the active site of NDM-1. To avoid the buffer
173 component effect, all the NDM-1 structures were determined in the same buffer component
174 but at different pHs. The crystals could be easily obtained by seeding in Bis-Tris buffer at
175 different pHs, but with unidentifiable electron density at the active site at a lower pH
176 (probably Bis-Tris but cannot be clearly modelled). To avoid potential perturbation of Bis-
177 Tris to the active site, we then optimized the crystallization in succinate buffer and got the
178 crystals at pH 5.5, 6.5 and 7.5. Although in crystals at pH5.5 and 6.5, succinate was observed
179 at the active site, it can be clearly modelled with one hydroxyl group coordinated to Zn2 and
180 substituting an apical water. This kind of interaction did not affect the other coordination
181 bonds at the active site (Figure S3). Comparison of structures in succinate at pH5.5, 6.5 and
182 7.5 (Figure 2B) depicted a prominent decrease of the Zn1-Zn2 distances from 3.95, 3.78 to
183 3.59 Å (Table 2). To further confirm this pH effect, crystals obtained at pH5.5 were soaked in
184 the cryo-protectant at pH7.5, which yielded a structure with the Zn1-Zn2 distance changed
185 from 3.95 to 3.53 Å, indicating a consistent pH effect on the active site. Besides the clear
186 tendency of Zn1-Zn2 changes according to different pHs, we also observed the decrease of
187 OH-Zn2 distance along with the pH increase which is consistent with the Zn1-Zn2 changes
188 (Table 2). However, Zn1-OH distances remain almost identical in all crystals we obtained
189 and reported by others (1.99 ± 0.07 Å). Although in some structures this hydroxide was
190 modelled as a water molecule, the shorter distance with Zn1 in all the structures indicates it
191 should be a hydroxide. Furthermore, QM/MM study showed that if a water molecule

192 coordinates between the two zinc ions, the distance of Zn1-Zn2 will be 5.6 Å(23), much
193 longer than those of all currently observed active sites. And the observed shorter Zn1-OH
194 distance is also consistent with the mostly accepted idea that this hydroxide is mainly
195 activated by Zn1 and acts as a nucleophile during the C-N bond break of β-lactam hydrolysis.

196 **MD simulations**

197 The distance of Zn1-Zn2 observed in different NDM-1 structures was also assessed by in
198 silico calculations. MD simulations starting from the enzyme/hydrolyzed ampicillin
199 structures (PDB: 5ZGE, 5ZGP, 5ZGR) were run to compare with experimental results. The
200 energy minimized structures in different pH states presented similar Zn1-Zn2 distances of 4.7
201 Å (pH 5.5), 4.7 Å (pH 6.2) and 4.8 Å (pH 7.3). These results are very close to the
202 experimentally determined distance of 4.6 Å, and do not show pH-dependence. The
203 differences of Zn1-Zn2 distance observed in native NDM-1 at different pHs were also
204 supported by our molecular dynamics analyses. Energy minimization showed Zn1-Zn2
205 distances of 3.9 Å, 3.7 Å and 3.5 Å for native NDM-1 at pH5.5, 6.5 and 7.5, respectively.
206 Despite of subtle differences, the changing tendency of Zn1-Zn2 distances is consistent with
207 the experimentally observed values. Previous QM/MM studies also calculated the Zn1-Zn2
208 distance of 3.58 Å(12), 3.60 Å (23) or 3.62 Å(40) in native NDM-1 although pH values were
209 not reported in these studies. We also modelled an intact ampicillin molecule into the active
210 site of native NDM-1 and performed MD simulations at different pHs which presented Zn1-
211 Zn2 distances of 4.8Å (pH5.5), 3.8Å (pH6.5) and 3.4Å (pH7.5), respectively. The consistent
212 decrease of Zn1-Zn2 distance in NDM-1/ampicillin models along with pH increase is similar
213 to that observed for native unbound NDM-1, and well correlates to the enzymatic activity of
214 NDM-1 at different pH (discussed later).

215 Overall, our results reveal that the longer distance in enzyme/hydrolyzed penam or
216 cephalosporin complexes is an intrinsic feature of NDM-1 and Zn1-Zn2 distance in native

217 enzyme is affected by crystal packing, pH and buffer components. Next, we examined if the
218 Zn1-Zn2 distance variation affects the enzymatic activity of NDM-1.

219 **Enzymatic study of NDM-1**

220 We first measured the enzymatic activity of wild type NDM-1 at different pHs (5.5, 6.5
221 and 7.5) prepared all with succinate to avoid the influence of buffer components. Imipenem
222 was used as the substrate and the k_{cat} values of NDM-1 at pH5.5, 6.5 and 7.5 are 1283, 2060
223 and 3960 S^{-1} , respectively, roughly 2-fold for each pH increase (K_M and K_{cat}/K_M parameters
224 are listed in Table 3). The same pattern of increase was also observed using a buffer prepared
225 with Bis-Tris in our assays and in other reports(23) although the specific values are different
226 depending on substrates and assay conditions. It is interesting to note that along with pH
227 increase, the enzymatic activity increases while Zn1-Zn2 distance shortens. In general,
228 buffer pH may affect enzyme activity through charge changes on residues at the active site
229 which may influence all the steps involved in enzyme catalysis including substrate binding,
230 intermediate formation and product release. The facts that almost identical zinc coordination
231 bonds, in particular the Zn1-OH distances ($1.99 \pm 0.07\text{ \AA}$) and geometries are kept in all
232 native structures obtained in different pHs (Table S3) and that identical product-enzyme
233 interactions are also observed in structures at different pHs (Figure 1), indicate that charge
234 effect on the active site residues might be very subtle or indirect. The only obvious
235 conformational change observed in these native structures at different pHs is the Zn1-Zn2
236 distance variation. Through careful structural comparison, we notice that the Zn2
237 coordination residue H250 progressively pushes Zn2 toward the active center from low to
238 high pH (Figure 2B). Residue H250 locates at the tip of loop 12 which is relatively mobile
239 among the structures at different pHs and has several charged residues at the other end.
240 Through this long range interaction, we speculate that pH may fine tune Zn2 position and
241 hence affect the enzymatic activity of NDM-1.

242 **Mutagenesis studies to modulate the enzymatic activity and active site conformation**

243 To further validate this speculation and test if modulation of the Zn1-Zn2 distance may
244 affect the enzyme activity, site-directed mutants of NDM-1 were generated and their
245 enzymatic activities were measured. To avoid possible perturbation of the active site
246 coordination and substrate binding, only second shell residues of the active site were mutated.
247 Through careful structural inspection, residues A121 and Q123 were selected for mutagenesis
248 studies. While both A121F and Q123G showed lower enzymatic activities, only Q123G was
249 successfully crystallized. As shown in Table 3, the K_{cat} value for the Q123G mutant was 686
250 s^{-1} , much lower than that of wild type NDM-1 with the same assay condition (1814 s^{-1}).

251 The active site flexibility of Q123G mutant was evaluated experimentally by measuring
252 the Zn1-Zn2 distance in high resolution crystal structures. We have successfully got the
253 structure of the Q123G mutant at pH7.5 in succinate buffer at the resolution of 1.2Å. The
254 overall structure of Q123G superimposed well to that of wild type NDM-1 with rmsd value
255 of 0.44 Å for all C α atoms and only minor flexibility in L3 loop was observed (Figure 3A).
256 The Q123G mutation did not perturb the active site conformations nor the interactions around
257 Q123 in wild type NDM-1 (Figure 3B). The Zn1-Zn2 distance in the Q123G mutant was
258 measured to be 3.84 Å, a value longer than that of wild type NDM-1 at pH7.5 (3.59/3.53Å)
259 and near that of wild type NDM-1 at pH6.5 (3.78Å). The enzymatic activity of the Q123G
260 mutant is much lower than that of wild type NDM-1 at pH7.5 but near the proportional value
261 of NDM-1 at pH6.5. In our enzymatic assay, imipenem was used as substrate. Measuring
262 from the recently published structure of NDM-1 in complex with imipenem(29), the side
263 chain of residue Q123 makes no contacts with imipenem and therefore would not affect its
264 binding with the active site nor the release of hydrolyzed product. The activity decrease of
265 the Q123G mutant should be solely attributed to the increase of Zn1-Zn2 distance, validating

266 our notion that modulation of the Zn1-Zn2 distance will affect the enzymatic activity of
267 NDM-1.

268 **Discussion**

269 As revealed in the crystallographic structures, the active site of NDM-1, especially the
270 Zn1-Zn2, is in a dynamic or oscillation state, depending on the environmental factors such as
271 crystal packing, pH and buffer components. This is also observed in a single crystal(18)
272 (PDB 3SPU) where there are 5 molecules in the asymmetric unit with 5 different Zn1-Zn2
273 distances ranging from 3.56 to 3.97 Å. And our enzymatic assays clearly show that the Zn1-
274 Zn2 distance correlates to the enzymatic activity of NDM-1 with shorter Zn1-Zn2 distance in
275 native NDM-1 having higher enzymatic activity. Interestingly, the distances of Zn1-Zn2 in
276 enzyme/product complexes are all at the same value of 4.6 Å. Thus, its relation to enzymatic
277 activity can be conveyed that bigger fluctuation (shorter Zn1-Zn2 distance) will favor higher
278 enzymatic activity, or in other words, the fluctuation of Zn1-Zn2 promotes the enzymatic
279 activity of NDM-1. The oscillation of Zn1-Zn2 distance during the enzymatic turnover was
280 observed in mechanism studies of the subclass B3 MBL L1(41) and QM/MM calculations of
281 NDM-1(24, 36), but here we attributed for the first time that such oscillations affect
282 enzymatic turnover.

283 In previous mutagenesis and structural study of another B1 MBL BCII, Vila and
284 coworkers also noticed that the active site conformational changes correlated the enzymatic
285 activity of BCII and proposed that fine tuning of Zn2 position was responsible for the activity
286 change of BCII(42-44). Comparison among the wild type and mutant BCII structures shows
287 that the Zn1-Zn2 distances in activity impaired BCII (BCII/HD, PDB code 2NYP), wild type
288 BCII (4C09/1BCII) and activity enhanced BCII (M5, PDB code 3FCZ) are 4.73, 3.50/3.85
289 and 3.32 Å, respectively. The relationship between enzymatic activity and Zn1-Zn2 distance
290 in BCII well supports our notions in NDM-1 with shorter Zn1-Zn2 distance favoring higher

291 activity. Although fine tuning of Zn2 position can also explain the structure-activity
292 relationship, Zn1-Zn2 distance variation is more specific. Considering that Zn1 also
293 contributes to the conformational changes albeit at a less extent than Zn2 (Figure 2B), Zn1-
294 Zn2 distance variation seems more accurate to explain current observations.

295 It is well known that conformational fluctuations are essential for substrate binding,
296 product release and even can be rate-limiting step in enzymatic reactions. However, the role
297 of conformational fluctuation along the reaction pathway was not well recognized. In this
298 study, through series of crystallographic, biochemical and biophysical studies and simulation
299 analyses, we presented a dynamic active site of NDM-1 which well correlates to its enzymatic
300 activity and proved that conformational fluctuation of the active site facilitates the enzymatic
301 reaction. This phenomenon was also observed in dihydrofolate reductase where
302 conformational fluctuation of an active site loop enhances its activity(45). In contrast to the
303 covalently bonded active site residues in dihydrofolate reductase, the conformational
304 fluctuation of the active site in NDM-1 is mainly presented by two noncovalently bonded
305 metal ions. The active site fluctuation may facilitate the enzyme to sample high-energy
306 conformational substrates that are conducive to form the transition state and promote the
307 enzymatic reaction(45). Our combinational studies reveal that modulation of the active site
308 fluctuation do affect the enzymatic activity of NDM-1, which may provide clues for future
309 inhibitor design. For example, Zn1-Zn2 fluctuation may be restricted to a certain state by
310 coordinating chemicals like substrate analogues as shown in a recent study(32, 46).

311 In summary, through the combination of crystallographic determination, biochemical and
312 biophysical measurements, site-directed mutagenesis and in silico simulation, our results
313 reveal that: 1) the longer distance of Zn1-Zn2 (4.6 Å) in enzyme/product complex is an
314 intrinsic feature of NDM-1; 2) the Zn1-Zn2 distance in native NDM-1 varies depending on
315 external factors like crystal packing, pH and buffer components; 3) the variation of Zn1-Zn2

316 distance affects the enzymatic activity of NDM-1 with shorter distance favoring higher
317 enzymatic activity.

318 **Materials and Methods**

319 *Protein expression, purification and site-directed mutagenesis*

320 Wild type *NDM-1* (G29-R270) was cloned into a His-MBP vector to facilitate protein folding and
321 purification. The fusion construct was expressed in *E. coli* BL21 (DE3) and the cells were allowed to
322 grown up to OD600 of 0.6 followed by induction of 0.5 mM IPTG overnight at 16 °C. After
323 centrifugation, cell pellet was suspended in lysis buffer of 20 mM HEPES pH 7.4, 0.5 M sodium
324 chloride for sonication. The supernatant was loaded to a nickel-NTA chromatography column (GE
325 healthcare) and NDM-1 was purified by an imidazole gradient. Effluents from nickel column were
326 further purified by a MBP column. The fusion tag was cleaved with TEV protease and separated from
327 NDM-1 by passing through a Ni-NTA column again. NDM-1 was in the flow-through fraction and
328 was further purified by a Q-sepharose ion exchange column (GE healthcare) at pH 7.0 with a sodium
329 chloride gradient from 0 to 0.3 M. The purified protein was buffer-exchanged into 50 mM NaCl and
330 concentrated to 100 mg/ml (measured at OD280 using an extinction coefficient of 27960) for later use.

331 For site-directed mutagenesis, wild type NDM-1 was used as the template and the mutations were
332 introduced using the quick-change method. The mutants were confirmed by sequencing and the
333 expression and purification of the mutant proteins were performed as same as that of wild type NDM-
334 1.

335 *Crystallization, diffraction data collection and structure refinement*

336 Wild type NDM-1 crystals were screened by sitting drop vapor diffusion method. NDM-1 in
337 complex with ampicillin crystals were observed in several conditions and were further optimized by
338 hanging drop method. Crystals for native NDM-1 were obtained in two forms with form 1 having one
339 molecule per asymmetric unit and form 2 having two molecules per asymmetric unit. The detailed
340 crystallization and cryo-protection conditions were listed in Table S1. All crystals were cryo-
341 protected and then flash frozen in liquid nitrogen. The diffraction data were collected at 100 K on
342 station BL17U1 or BL19U1 at the Shanghai Synchrotron Radiation Facility and processed with

343 HKL2000(47). The structures were solved by molecular replacement method using the previously
344 solved NDM-1/Amp complex(16) (PDB code 3Q6X) as searching model. The models were refined
345 with Refmac(48, 49) in the CCP4 suite(50) and then cycled with rebuilding in Coot(51). TLS
346 refinement(52) was incorporated into the later stages of the refinement process. Solvents were added
347 automatically in Coot and then manually inspected and modified. The final models were analyzed
348 with MolProbity(53) showing that almost all amino acid residues were in favored regions of the
349 Ramachandran plot while residues D90 were in a forbidden region as noticed previously(16). Data
350 collection and model refinement statistics for all datasets were summarized in **Table S2**. The
351 coordinates and structure factors were deposited in the Protein Data Bank with entry codes also listed
352 in **Table S2**.

353 *Enzymatic activity measurement*

354 Hydrolysis of antibiotics by wild type and mutant NDM-1 were monitored by detecting a reduction
355 in the absorbance that resulted from the opening of the β -lactam ring using imipenem as substrate(39).
356 Activity for the pH dependence of wild type NDM-1 was measured in a reaction buffer containing 50
357 mM succinate (pH5.5, 6.5 or 7.5), 100 mM NaCl, 50 μ M ZnCl₂, 10 μ g/ml BSA, 50 nM NDM-1 and
358 varying concentrations of imipenem. The comparison of enzymatic activity between wild type and
359 mutant NDM-1 was assayed in a reaction buffer containing 50 mM HEPES (pH7.5), 100 mM NaCl,
360 100 μ M ZnCl₂, 10 μ g/ml BSA, 50 nM enzymes and varying concentrations of imipenem. All the
361 experiments were performed at 25°C and the A300 value was immediately measured using a
362 perkinelmer spectrophotometer enspire. Kinetic parameters were determined by plotting the initial
363 velocities against substrate concentrations and curve fitting with the Graphpad prism5 software. All
364 measurements were repeated three times and the average values were presented.

365 *Simulation*

366 The native models were taken from the crystal structures solved in succinate buffer at
367 pH5.5, 6.5 and 7.5, respectively. The enzyme/product models were taken from structures
368 solved at pH5.5 (PDB code 5ZGE), pH6.2 (5ZGP) and pH7.3 (5ZGR), respectively. NDM-1
369 in complex with hydrolyzed ampicillin was superimposed onto the native models. The

370 coordinates of hydrolyzed ampicillin were kept and the chemical structure was modified to
371 generate the substrate ampicillin. Then we got the initial models of three enzyme-substrate
372 systems at different pHs. All the water molecules, solvent and succinate molecules in crystal
373 structures were removed from the initial models, and the shared coordination hydroxide was
374 kept. Polar hydrogens were added to the systems using *H++* web-server(54).

375 MD simulations were carried out using Amber 12(55). The script MCPB.py(56) was
376 applied to generate parameters of the above models for further MD simulation. The ff14SB
377 force field was used for the protein systems(57). Each model was then solvated in a periodic
378 box surrounded by no less than 10 Å TIP3P water molecules(58). Counter ions were added to
379 maintain neutral charge of systems. To remove possible poor contacts between the solute and
380 solvent, energy minimizations using a combination of the steepest descent and conjugated
381 gradient method was performed. For models with ampicillin, each system was subjected to a
382 slow heating process for 500 ps from 0 to 300K and then was equilibrated for 500 ps under a
383 NPT ensemble at a constant temperature of 300 K. Finally, production MD simulations were
384 conducted for 20ns. The Sander program was used to conduct the MD simulation at constant
385 temperature (300 K) and pressure (1.0 atm) with a time step of 1 fs. The non-bonded cutoff
386 was set to 12.0 Å, and electrostatic interactions were calculated using the particle-mesh
387 Ewald method(59). The SHAKE algorithm(60) was used to constrain bonds involving
388 hydrogen atoms.

389

390 **Supporting Information**

391 Figure S1. Superposition of overall structures of NDM-1 in complex with hydrolyzed
392 antibiotics. (file type, TIFF)

393 Figure S2. Active site conformations of NDM-1 in complex with hydrolyzed antibiotics. (file
394 type, TIFF)

395 Figure S3. Superposition of the overall structures of native NDM-1 crystallized in form2.

396 (file type, TIFF)

397 Figure S4. Active sites of native NDM-1 crystallized in succinate at pH5.5 and pH6.5. (file

398 type, TIFF)

399 Table S1. Crystallization conditions and cryoprotectants for NDM-1 crystals. (file type, DOC)

400 Table S2. Data collection and refinement statistics. (file type, DOC)

401 Table S3. Active site coordination of wild type and mutant NDM-1. (file type, DOC)

402

403 **Author contributions**

404 HZ and QH designed the experiments. HZ and GM performed the crystallography work. YZ,

405 CW, BP, HF and LZ performed the biochemical and biophysical assays. LZ and AA

406 performed the computation work. HZ and QH wrote the manuscript. All authors approved the

407 manuscript.

408

409 **Acknowledgements**

410 This work was supported by Natural Science Foundation of China grant (31670753 to HZ),

411 Guangdong Science and Technology Program (2017B030301018 to HZ), research grants from

412 Shenzhen Science and Technology Innovation Committee (JCYJ20160608140912962 and

413 ZDSYS20140509142721429 to HZ), the Health and Medical Research Fund of Hong Kong

414 (15140992 to QH), the Hong Kong RGC grants (C5026-16G and AoE/P-705/16 to QH),

415 Natural Science Foundation of Guangdong Province (2016A030313053 to LZ) and the

416 Special Fund for Development of Strategic Emerging Industries in Shenzhen

417 (JCYJ20160520174823939 to LZ). We thank the staff from BL17U1 and BL19U1 beamlines

418 at Shanghai Synchrotron Radiation Facility for technical support.

419

420 **Conflict of interest**

421 The authors declare that they have no conflicts of interest in the contents of this article.

422 **References**

423

- 424 1. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. *Clin*
425 *Microbiol Rev* 23:160-201.
- 426 2. Page MI. 1999. The reactivity of beta-lactams, the mechanism of catalysis and the
427 inhibition of beta-lactamases. *Curr Pharm Des* 5:895-913.
- 428 3. Fisher JF, Meroueh SO, Mobashery S. 2005. Bacterial resistance to beta-lactam
429 antibiotics: compelling opportunism, compelling opportunity. *Chem Rev* 105:395-
430 424.
- 431 4. Llarrull LI, Testero SA, Fisher JF, Mobashery S. 2010. The future of the beta-lactams.
432 *Curr Opin Microbiol* 13:551-7.
- 433 5. Bush K, Jacoby GA. 2010. Updated functional classification of beta-lactamases.
434 *Antimicrob Agents Chemother* 54:969-76.
- 435 6. Mojica MF, Bonomo RA, Fast W. 2016. B1-Metallo-beta-Lactamases: Where Do We
436 Stand? *Curr Drug Targets* 17:1029-50.
- 437 7. Johnson AP, Woodford N. 2013. Global spread of antibiotic resistance: the example
438 of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. *J*
439 *Med Microbiol* 62:499-513.
- 440 8. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009.
441 Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel
442 erythromycin esterase gene carried on a unique genetic structure in *Klebsiella*
443 *pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother* 53:5046-
444 54.
- 445 9. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. 2016. Global Dissemination of
446 Carbapenemase-Producing *Klebsiella pneumoniae*: Epidemiology, Genetic Context,
447 Treatment Options, and Detection Methods. *Front Microbiol* 7:895.
- 448 10. Walsh TR, Weeks J, Livermore DM, Toleman MA. 2011. Dissemination of NDM-1
449 positive bacteria in the New Delhi environment and its implications for human health:
450 an environmental point prevalence study. *Lancet Infect Dis* 11:355-62.
- 451 11. Toleman MA, Bugert JJ, Nizam SA. 2015. Extensively drug-resistant New Delhi
452 metallo-beta-lactamase-encoding bacteria in the environment, Dhaka, Bangladesh,
453 2012. *Emerg Infect Dis* 21:1027-30.
- 454 12. Thomas PW, Zheng M, Wu S, Guo H, Liu D, Xu D, Fast W. 2011. Characterization of
455 purified New Delhi metallo-beta-lactamase-1. *Biochemistry* 50:10102-13.
- 456 13. Li T, Wang Q, Chen F, Li X, Luo S, Fang H, Wang D, Li Z, Hou X, Wang H. 2013.
457 Biochemical characteristics of New Delhi metallo-beta-lactamase-1 show unexpected
458 difference to other MBLs. *PLoS One* 8:e61914.
- 459 14. Chen J, Chen H, Shi Y, Hu F, Lao X, Gao X, Zheng H, Yao W. 2013. Probing the effect of
460 the non-active-site mutation Y229W in New Delhi metallo-beta-lactamase-1 by site-
461 directed mutagenesis, kinetic studies, and molecular dynamics simulations. *PLoS One*
462 8:e82080.

- 463 15. Marcocchia F, Bottoni C, Sabatini A, Colapietro M, Mercuri PS, Galleni M, Kerff F,
464 Matagne A, Celenza G, Amicosante G, Perilli M. 2016. Kinetic Study of Laboratory
465 Mutants of NDM-1 Metallo-beta-Lactamase and the Importance of an Isoleucine at
466 Position 35. *Antimicrob Agents Chemother* 60:2366-72.
- 467 16. Zhang H, Hao Q. 2011. Crystal structure of NDM-1 reveals a common beta-lactam
468 hydrolysis mechanism. *FASEB J* 25:2574-82.
- 469 17. Zheng B, Tan S, Gao J, Han H, Liu J, Lu G, Liu D, Yi Y, Zhu B, Gao GF. 2011. An
470 unexpected similarity between antibiotic-resistant NDM-1 and beta-lactamase II
471 from *Erythrobacter litoralis*. *Protein Cell* 2:250-8.
- 472 18. King D, Strynadka N. 2011. Crystal structure of New Delhi metallo-beta-lactamase
473 reveals molecular basis for antibiotic resistance. *Protein Sci* 20:1484-91.
- 474 19. Kim Y, Tesar C, Mire J, Jedrzejczak R, Binkowski A, Babnigg G, Sacchettini J,
475 Joachimiak A. 2011. Structure of apo- and monometalated forms of NDM-1--a highly
476 potent carbapenem-hydrolyzing metallo-beta-lactamase. *PLoS One* 6:e24621.
- 477 20. Green VL, Verma A, Owens RJ, Phillips SE, Carr SB. 2011. Structure of New Delhi
478 metallo-beta-lactamase 1 (NDM-1). *Acta Crystallogr Sect F Struct Biol Cryst Commun*
479 67:1160-4.
- 480 21. Yang H, Aitha M, Hetrick AM, Richmond TK, Tierney DL, Crowder MW. 2012.
481 Mechanistic and spectroscopic studies of metallo-beta-lactamase NDM-1.
482 *Biochemistry* 51:3839-47.
- 483 22. King DT, Worrall LJ, Gruninger R, Strynadka NC. 2012. New Delhi metallo-beta-
484 lactamase: structural insights into beta-lactam recognition and inhibition. *J Am Chem*
485 *Soc* 134:11362-5.
- 486 23. Kim Y, Cunningham MA, Mire J, Tesar C, Sacchettini J, Joachimiak A. 2013. NDM-1,
487 the ultimate promiscuous enzyme: substrate recognition and catalytic mechanism.
488 *FASEB J* 27:1917-27.
- 489 24. Zheng M, Xu D. 2013. New Delhi metallo-beta-lactamase I: substrate binding and
490 catalytic mechanism. *J Phys Chem B* 117:11596-607.
- 491 25. Yang H, Young H, Yu S, Sutton L, Crowder MW. 2014. Targeting metallo-
492 carbapenemases via modulation of electronic properties of cephalosporins. *Biochem*
493 *J* 464:271-9.
- 494 26. Yang H, Aitha M, Marts AR, Hetrick A, Bennett B, Crowder MW, Tierney DL. 2014.
495 Spectroscopic and mechanistic studies of heterodimetallic forms of metallo-beta-
496 lactamase NDM-1. *J Am Chem Soc* 136:7273-85.
- 497 27. Feng H, Ding J, Zhu D, Liu X, Xu X, Zhang Y, Zang S, Wang DC, Liu W. 2014. Structural
498 and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins. *J Am*
499 *Chem Soc* 136:14694-7.
- 500 28. Das CK, Nair NN. 2017. Hydrolysis of cephalexin and meropenem by New Delhi
501 metallo-beta-lactamase: the substrate protonation mechanism is drug dependent.
502 *Phys Chem Chem Phys* 19:13111-13121.
- 503 29. Feng H, Liu X, Wang S, Fleming J, Wang DC, Liu W. 2017. The mechanism of NDM-1-
504 catalyzed carbapenem hydrolysis is distinct from that of penicillin or cephalosporin
505 hydrolysis. *Nat Commun* 8:2242.
- 506 30. Serag MF, Abadi M, Habuchi S. 2014. Single-molecule diffusion and conformational
507 dynamics by spatial integration of temporal fluctuations. *Nat Commun* 5:5123.
- 508 31. Thomas PW, Cammarata M, Brodbelt JS, Fast W. 2014. Covalent inhibition of New
509 Delhi metallo-beta-lactamase-1 (NDM-1) by cefaclor. *Chembiochem* 15:2541-8.

- 510 32. Gonzalez MM, Kosmopoulou M, Mojica MF, Castillo V, Hinchliffe P, Pettinati I, Brem J,
511 Schofield CJ, Mahler G, Bonomo RA, Llarrull LI, Spencer J, Vila AJ. 2015.
512 Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1
513 Carbapenemase. *ACS Infect Dis* 1:544-54.
- 514 33. Klingler FM, Wichelhaus TA, Frank D, Cuesta-Bernal J, El-Delik J, Muller HF, Sjuts H,
515 Gottig S, Koenigs A, Pos KM, Pogoryelov D, Proschak E. 2015. Approved Drugs
516 Containing Thiols as Inhibitors of Metallo-beta-lactamases: Strategy To Combat
517 Multidrug-Resistant Bacteria. *J Med Chem* 58:3626-30.
- 518 34. Christopheit T, Leiros HK. 2016. Fragment-based discovery of inhibitor scaffolds
519 targeting the metallo-beta-lactamases NDM-1 and VIM-2. *Bioorg Med Chem Lett*
520 26:1973-7.
- 521 35. Groundwater PW, Xu S, Lai F, Varadi L, Tan J, Perry JD, Hibbs DE. 2016. New Delhi
522 metallo-beta-lactamase-1: structure, inhibitors and detection of producers. *Future*
523 *Med Chem* 8:993-1012.
- 524 36. Zhu K, Lu J, Liang Z, Kong X, Ye F, Jin L, Geng H, Chen Y, Zheng M, Jiang H, Li JQ, Luo C.
525 2013. A quantum mechanics/molecular mechanics study on the hydrolysis
526 mechanism of New Delhi metallo-beta-lactamase-1. *J Comput Aided Mol Des*
527 27:247-56.
- 528 37. Lisa MN, Palacios AR, Aitha M, Gonzalez MM, Moreno DM, Crowder MW, Bonomo
529 RA, Spencer J, Tierney DL, Llarrull LI, Vila AJ. 2017. A general reaction mechanism for
530 carbapenem hydrolysis by mononuclear and binuclear metallo-beta-lactamases. *Nat*
531 *Commun* 8:538.
- 532 38. Yuan Q, He L, Ke H. 2012. A potential substrate binding conformation of beta-
533 lactams and insight into the broad spectrum of NDM-1 activity. *Antimicrob Agents*
534 *Chemother* 56:5157-63.
- 535 39. Guo Y, Wang J, Niu G, Shui W, Sun Y, Zhou H, Zhang Y, Yang C, Lou Z, Rao Z. 2011. A
536 structural view of the antibiotic degradation enzyme NDM-1 from a superbug.
537 *Protein Cell* 2:384-94.
- 538 40. Chen J, Chen H, Zhu T, Zhou D, Zhang F, Lao X, Zheng H. 2014. Asp120Asn mutation
539 impairs the catalytic activity of NDM-1 metallo-beta-lactamase: experimental and
540 computational study. *Phys Chem Chem Phys* 16:6709-16.
- 541 41. Breece RM, Hu Z, Bennett B, Crowder MW, Tierney DL. 2009. Motion of the zinc ions
542 in catalysis by a dizinc metallo-beta-lactamase. *J Am Chem Soc* 131:11642-3.
- 543 42. Tomatis PE, Rasia RM, Segovia L, Vila AJ. 2005. Mimicking natural evolution in
544 metallo-beta-lactamases through second-shell ligand mutations. *Proc Natl Acad Sci U*
545 *S A* 102:13761-6.
- 546 43. Gonzalez JM, Medrano Martin FJ, Costello AL, Tierney DL, Vila AJ. 2007. The Zn2
547 position in metallo-beta-lactamases is critical for activity: a study on chimeric metal
548 sites on a conserved protein scaffold. *J Mol Biol* 373:1141-56.
- 549 44. Tomatis PE, Fabiane SM, Simona F, Carloni P, Sutton BJ, Vila AJ. 2008. Adaptive
550 protein evolution grants organismal fitness by improving catalysis and flexibility.
551 *Proc Natl Acad Sci U S A* 105:20605-10.
- 552 45. Bhabha G, Lee J, Ekiert DC, Gam J, Wilson IA, Dyson HJ, Benkovic SJ, Wright PE. 2011.
553 A dynamic knockout reveals that conformational fluctuations influence the chemical
554 step of enzyme catalysis. *Science* 332:234-8.
- 555 46. Hinchliffe P, Gonzalez MM, Mojica MF, Gonzalez JM, Castillo V, Saiz C, Kosmopoulou
556 M, Tooke CL, Llarrull LI, Mahler G, Bonomo RA, Vila AJ, Spencer J. 2016. Cross-class

557 metallo-beta-lactamase inhibition by bisthiazolidines reveals multiple binding modes.
558 Proc Natl Acad Sci U S A 113:E3745-54.

559 47. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in
560 oscillation mode. *Methods in enzymology*:307-325.

561 48. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular
562 structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr*
563 53:240-55.

564 49. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD,
565 Long F, Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal
566 structures. *Acta Crystallogr D Biol Crystallogr* 67:355-67.

567 50. Collaborative Computational Project N. 1994. The CCP4 suite: programs for protein
568 crystallography. *Acta Crystallogr D Biol Crystallogr* 50:760-3.

569 51. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot.
570 *Acta Crystallogr D Biol Crystallogr* 66:486-501.

571 52. Painter J, Merritt E. 2006. TLSMD web server for the generation of multi-group TLS
572 models. *Journal of Applied Crystallography* 39:109-111.

573 53. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray
574 LW, Richardson JS, Richardson DC. 2010. MolProbity: all-atom structure validation
575 for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* 66:12-21.

576 54. Anandakrishnan R, Aguilar B, Onufriev AV. 2012. H++3.0: automating pK prediction
577 and the preparation of biomolecular structures for atomistic molecular modeling
578 and simulations. *Nucleic Acids Research* 40:W537-W541.

579 55. Case DA, Darden TA, Cheatham III TE, Simmerling CL, Wang J, Duke RE, Luo R, Walker
580 RC, Zhang W, Merz KM, Roberts S, Wang B, Hayik S, Roitberg A, Seabra G, Swails J,
581 Götz AW, Kolossvary I, Wong KF, Paesani F, Vanicek J, Wolf RM, Liu J, Wu X, Brozell
582 SR, Steinbrecher T, Gohlke H, Cai Q, Ye X, Wang J, Hsieh M-J, Hornak V, Cui G, Roe DR,
583 Mathews DH, Seetin MG, Salomon-Ferrer R, Sagui C, Babin V, Luchko T, Gusarov S,
584 Kovalenko A, Kollman PA. 2012. AMBER 12, University of California, San Francisco.

585 56. Li PF, Merz KM. 2016. MCPB.py: A Python Based Metal Center Parameter Builder.
586 *Journal of Chemical Information and Modeling* 56:599-604.

587 57. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. 2015.
588 ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from
589 ff99SB. *Journal of Chemical Theory and Computation* 11:3696-3713.

590 58. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. 1983. Comparison
591 of Simple Potential Functions for Simulating Liquid Water. *Journal of Chemical*
592 *Physics* 79:926-935.

593 59. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. 1995. A Smooth
594 Particle Mesh Ewald Method. *Journal of Chemical Physics* 103:8577-8593.


595 60. Ryckaert JP, Ciccotti G, Berendsen HJC. 1977. Numerical-Integration of Cartesian
596 Equations of Motion of a System with Constraints - Molecular-Dynamics of N-
597 Alkanes. *Journal of Computational Physics* 23:327-341.

598

599

600 **Figure legends**

601



602

603 Figure 1. Active site conformation of NDM-1 in complex with hydrolyzed ampicillin

604 crystallized at pH5.5 (A) and superposition of the active sites of NDM-1 crystallized at

605 different conditions (B). Active site residues and hydrolyzed ampicillin were shown as ball-

606 and-stick models. The residues were colored with grey carbons, the hydrolyzed ampicillin


607 was colored with green and cyan carbons in (A) and (B), respectively. Zinc ions and

608 hydroxide were shown as grey and red balls, respectively. Coordination bonds between zinc

609 ions and active site residues were shown as yellow dash lines. The distances between Zn1-

610 OH, OH-Zn2 and Zn1-Zn2 were 2.1, 3.0 and 4.6Å (shown as red dashed lines), respectively.

611




612

613 Figure 2. Active site conformations of native NDM-1. Active site residues were shown as
 614 ball-and-stick models while zinc ions and hydroxide at the active site were shown as spheres.

615 Coordination bonds were shown as yellow dash lines. (A) Superposition of active sites of 8
 616 native NDM-1 crystallized in form2. The active site conformations are strikingly identical
 617 among structures from different crystallization conditions, especially the Zn1-OH, OH-Zn2
 618 and Zn1-Zn2 conformations and distances.

619 crystallized in form1 at pH5.5, 6.5 and 7.5 in succinate buffers. The zinc ions, hydroxide ion
 620 and carbon atoms in residue H250 were colored in green, cyan, red and magenta for crystals
 621 at pH5.5, 6.5, 7.5 and 7.5 (soaked at pH7.5 from crystals of pH5.5), respectively. Residue
 622 H250 pushes Zn2 to the active center along with pH increase. Residue D124 adjusts its side
 623 chain carboxylate group accordingly to coordinate to Zn2.

624



625

626 Figure 3. Structural comparison between wild type and Q123G mutant NDM-1. Q123G
 627 mutant NDM-1 was superimposed onto wild type NDM-1 (succinate, pH7.5, PDB code
 628 5ZGW). Active site residues were shown as ball-and-stick models while zinc ions and
 629 hydroxide at the active site were shown as spheres. Coordination bonds were shown as
 630 yellow dash lines. (A) Overall structural superimposition. L3 loops show flexibility between
 631 these two structures. (B) Active sites superimposition. The zinc ions, hydroxide ion and
 632 carbon atoms in residue H250 were colored in cyan and magenta for Q123G and wild type
 633 NDM-1, respectively. Q123G mutation did not perturb the active site conformation obviously.
 634 The distance of Zn1-Zn2 in Q123G is longer than that in wild type NDM-1.

635

Table 1. NDM-1 in complex with hydrolysed products

PDB	Complex	Resolution (Å)	M1-M2 distance(Å)	M1-OH distance(Å)	OH-M2 distance(Å)	Crystallization condition	Reference and remark
5ZGE	Ampicillin	1.00	4.60/4.61	2.08/2.09	2.98/2.94	0.1M Bis-Tris pH5.5, 0.2M Li ₂ SO ₄ , 25% PEG3350	This work
5ZGP	Ampicillin	1.15	4.59/4.59	1.97/1.94	2.99/3.04	0.1M Bis-Tris pH6.2, 0.2M Li ₂ SO ₄ , 15% PEG3350, 20 mg/ml ampicillin	This work
5ZGR	Ampicillin	1.15	4.59/4.59	1.98/1.99	3.01/3.04	0.1M HEPES pH7.3, 20% PEG3350, 20 mg/ml ampicillin	This work
5ZGQ	Ampicillin	1.50	4.58/4.57	1.99/1.97	3.04/3.04	0.1M Tris-HCl pH7.5, 25% PEG4000, 0.7M (NH ₄) ₂ SO ₄ , 20mg/ml ampicillin	This work
4EY2	Methicillin	1.17	4.57/4.58	1.95/1.97	2.99/3.00	0.2M MgCl ₂ , 25% PEG3350, 0.1M bis-tris pH5.5	(22)
4EYB	Oxacillin	1.16	4.54/4.55	1.98/1.96	2.94/2.98	0.2M MgCl ₂ , 25% PEG3350, 0.1M bis-tris pH5.5	(22)
4EYF	Benzylpenicillin	1.8	4.63/4.61	1.98/1.93	3.11/3.08	0.2M MgCl ₂ , 25% PEG3350, 0.1M bis-tris pH5.5	(22)
4RL2	Cefalexin	2.01	4.48/4.55	1.83/2.00	2.99/2.78	28% (w/v) PEG3350, 0.1 M Bis-Tris, pH 5.8, 0.2 M (NH ₄) ₂ SO ₄	(27)
4H0D	Ampicillin	1.5	4.48/4.49	2.08/2.09	2.79/2.79	0.2 M NaCl, 0.1 M HEPES pH 7.5, 25 % w/v PEG 3350, 10 mM MnCl₂	(23)
4HL2	Ampicillin	1.05	4.60/4.60	1.94/1.96	3.04/3.04	0.2 M (NH ₄) ₂ SO ₄ , 0.1 M Bis-Tris pH 5.5, 25% PEG 3350, 100 mM ampicillin	(23)
4RAW	Ampicillin	1.3	4.59/4.60	2.05/2.07	2.98/2.97	0.2 M NaCl, 0.1 M Tris pH 7.0, 30% PEG 3000, 5 mM CdCl ₂ , 200mg/ml ampicillin	Cd1-Cd2 at active site M67V
4RL0	Cefuroxime	1.3	3.81/3.83	2.01/2.03	2.16/2.17	30% PEG3350, 0.1M Bis-Tris pH 6.0, 0.2 M Li ₂ SO ₄	(27), C8 Coo ⁻ did not coordinate to zn1
4EYL	Meropenem	1.9	4.05/3.88	-	-	1M trisodium cacodylate, 0.1M sodium cacodylate pH 6.5	(22), C7 Coo ⁻ intercalates between two Zn ions
5N0H	Meropenem	1.9	4.01/3.83	2.04/2.08	2.66/2.15	1M trisodium cacodylate, 0.1M sodium cacodylate, pH 6.5	Intercalate between two Zn ions
4RBS	Meropenem	2.4	4.00/4.00	-	-	2.8 M sodium acetate pH 7.0	C3 Coo ⁻ did not coordinate to Zn2
5YPK	Imepenem	2.0	3.87~4.15	-	-	28% (w/v) PEG 3350, 0.1M Bis-Tris, pH 5.8, 0.2M ammonium sulfate	(29), EI2
5YPI	Imepenem	2.3	4.03~4.25	-	-	28% (w/v) PEG 3350, 0.1M Bis-Tris, pH 5.8, 0.2M ammonium sulfate	(29), EI1
5YPL	Imepenem	1.8	3.89/3.86	-	-	28% (w/v) PEG 3350, 0.1M Bis-Tris, pH 5.8, 0.2M ammonium sulfate	(29), EP, intercalation
5YPM	Meropenem	2.15	3.93~4.30	-	-	28% (w/v) PEG 3350, 0.1M Bis-Tris, pH 5.8, 0.2M ammonium sulfate	(29), EI1
5YPN	Meropenem	2.12	4.08/4.31	-	-	28% (w/v) PEG 3350, 0.1M Bis-Tris, pH 5.8, 0.2M ammonium sulfate	(29), EI2

639 **Table 2.** Active site conformations of native NDM-1 structures

PDB	Remark	Resolution (Å)	M1-M2 distance (Å)	M1-OH distance (Å)	OH-M2 distance (Å)	Coordinate error (Å)	Reference
5XP6	native, form 1 Succinate pH5.5	0.95	3.95	1.92	2.55	0.009	This work
5ZGI	native, form 1 Succinate pH6.5	0.98	3.78	1.93	2.35	0.011	This work
5ZGX	native, form 1 Succinate pH7.5	0.95	3.59	1.96	2.09	0.010	This work
5ZGW	native, form 1 Succinate pH7.5 (back soaked from pH5.5)	0.95	3.53	1.97	2.02	0.011	This work
5ZGF	Q123G, form1 Succinate pH7.5	1.20	3.84	1.90	2.43	0.029	This work
5ZGZ	native, form 1 Imidazole pH7.5	0.95	3.62	1.98	2.04	0.011	This work
5ZGY	native, form 1 Bis-Tris pH7.5	0.95	3.49	1.96	2.00	0.011	This work
5ZGU	native, form 2 HEPES pH7.0	1.55	3.43/3.42	2.11/2.11	2.13/2.12	0.049	This work
5ZGT	native, form 2 HEPES pH7.5	1.20	3.42/3.39	2.05/2.04	2.07/2.05	0.020	This work
5ZH1	native, form2 Imidazole pH7.5	1.05	3.41/3.42	1.93/1.95	1.96/1.95	0.022	This work
5ZGV	native, form2 Tris pH8.0	1.15	3.43/3.40	2.05/2.06	2.06/2.07	0.021	This work
3SPU	Amonium sulfate pH8.5	2.1	3.84/3.88/3.97/ 3.84/3.56	2.54/1.93/2.11/ 2.08/1.98	2.46/2.60/2.20/ 2.37/2.09		(18)
3ZR9	Zn-Cd pH7.5	1.91	3.64	1.93	2.38		(20)
5JQJ	Mutant, MgSO ₄ pH6.75	1.67	3.61	1.89	2.21		
4TZE	NDM-5 pH7.5	1.57	3.49/3.56	2.05/2.05	2.07/2.07		
4TZF	NDM-8 Bis-Tris pH5.5	1.22	3.70	2.00	2.13		
4TYF	NDM-4 pH7	1.10	3.54	1.89	2.03		
4RM5	D124N Tris pH7.5	2.1	4.01/4.10/4.10/ 4.11	2.61/2.53/2.85/ 2.58	2.60/2.72/2.72/ 2.57		(27)

641 Table 3 Enzymatic characterization of wild type and mutant NDM-1 using imipenem as
 642 substrate

	WT(pH5.5) succinate	WT(pH6.5) succinate	WT(pH7.5) succinate	WT(pH7.5) HEPES	A121F(pH7.5) HEPES	Q123G(pH7.5) HEPES
K _{cat} (s ⁻¹)	1283±85	2060±245	3960±160	1815±104	221±5.6	686±38
K _M (μM)	337±44	523±103	1415±72	560±52	55±4.6	201±28
K _{cat} /K _M (M ⁻¹ s ⁻¹)	3.82×10 ⁶	3.94×10 ⁶	2.80×10 ⁶	3.24×10 ⁶	4.02×10 ⁶	3.41×10 ⁶

643